Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 33
- Registration Number
- NCT03710460
- Locations
- 🇲🇽
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
- Conditions
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6263
- Registration Number
- NCT03619213
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 20
- Registration Number
- NCT03592667
- Locations
- 🇲🇽
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 48
- Registration Number
- NCT03565458
- Locations
- 🇰🇷
LG chem, Seoul, Gangseo-Gu, Korea, Republic of
Effect of Dapagliflozin on IAH in T1DM
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT03556033
- Locations
- 🇳🇱
Radboud university medical center, Nijmegen, Netherlands
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Celltrion Pharm, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT03499704
- Locations
- 🇰🇷
The Catholic University of Korea, Bucheon, St. Marys Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincents Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 714582
- Registration Number
- NCT03492580
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT03387683
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers
- First Posted Date
- 2017-12-07
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 123
- Registration Number
- NCT03364985
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Phase IV Study in Drug-Naive Patients With T2DM in China
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 304
- Registration Number
- NCT03344341
- Locations
- 🇨🇳
Research Site, Yinchuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.